Published in Clin Cancer Res on November 01, 2006
Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One (2011) 2.61
Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat Res (2011) 1.37
Large-scale parent-child comparison confirms a strong paternal influence on telomere length. Eur J Hum Genet (2009) 1.33
Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control (2009) 1.32
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol (2009) 1.29
Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort. EBioMedicine (2015) 1.27
Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One (2014) 0.83
The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity. Neoplasia (2014) 0.82
Telomere length, genetic variants and risk of squamous cell carcinoma of the head and neck in Southeast Chinese. Sci Rep (2016) 0.81
Disease drivers of aging. Ann N Y Acad Sci (2016) 0.81
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget (2016) 0.78
Telomere Length and Risk of Hepatocellular Carcinoma: A Nested Case-control Study in Taiwan Cancer Screening Program Cohort. Anticancer Res (2017) 0.75
Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes. BMC Cancer (2016) 0.75
How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol (2006) 1.81
Paternal age is positively linked to telomere length of children. Aging Cell (2005) 1.69
Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med (2008) 1.27
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23
Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.21
Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep (2012) 1.17
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2010) 1.14
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol (2008) 1.14
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer (2009) 1.14
Participation in cancer clinical trials: why are patients not participating? Med Decis Making (2013) 1.10
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05
Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer (2006) 1.01
Murine models of life span extension. Sci Aging Knowledge Environ (2004) 0.99
CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol (2011) 0.98
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (2011) 0.95
Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat (2012) 0.95
High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys (2011) 0.95
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol (2005) 0.95
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol (2012) 0.92
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol (2006) 0.91
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol (2011) 0.90
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat (2011) 0.90
Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med (2014) 0.89
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol (2014) 0.86
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC). Am J Clin Oncol (2014) 0.85
Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85
Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol (2010) 0.85
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs (2013) 0.85
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. Head Neck (2006) 0.84
Chemoprevention of breast cancer. Expert Rev Anticancer Ther (2008) 0.84
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol (2010) 0.83
Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol (2007) 0.83
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets (2012) 0.83
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol (2012) 0.83
Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells (2005) 0.82
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat (2014) 0.81
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat (2010) 0.79
A novel transcriptional inhibitory element differentially regulates the cyclin D1 gene in senescent cells. J Biol Chem (2002) 0.79
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78
Tumor cell apoptosis mediated by cytoplasmic ING1 is associated with improved survival in oral squamous cell carcinoma patients. Oncotarget (2014) 0.78
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol (2004) 0.77
Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep (2012) 0.77
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers (2013) 0.75
Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro. Stem Cells Dev (2004) 0.75
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol (2011) 0.75
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Clin Adv Hematol Oncol (2008) 0.75
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. Cancer Chemother Pharmacol (2009) 0.75
Introduction to special issue translational goals of neoadjuvant therapy. Breast Cancer Res Treat (2012) 0.75
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2011) 0.75